Amgen tested its drug in patients with the most common type of lung cancer, called non-small cell cancer. Sotorasib made the cancers shrink significantly in patients with the mutation, Amgen reported last week at the World Conference on Lung Cancer. KRAS mutations of some type are present in 90% of pancreatic tumours. With the KRAS mutation, the protein remains mostly in an “on” position, and cells are constantly forced to grow. The drug attached itself to cysteine, an amino acid that occurs in the groove only because of the KRAS mutation.

Source: bd News24 February 06, 2021 10:41 UTC